Global Orphan Drugs Market Report: 2016 Edition - New Report by Koncept Analytics

1
Global Orphan Drugs Market Report
----------------------------------------- 2016
View Report Details
2
View Report Details

• Executive Summary
• A rare disease is the one that occurs uncommonly
  or rarely in the general population. However,
  there exists no clear definition for categorizing
  rare diseases and is usually defined on the
  basis of the prevalence, and some other factors
  including the severity of disease and
  availability of treatment options. Rare diseases
  are often serious, chronic and progressive.
  Orphan drugs are medicinal products intended for
  the diagnosis, prevention or treatment of rare
  diseases. These drugs are referred to be orphan
  as under normal conditions because these drugs
  are not cost effective to be developed by the
  pharmaceuticals industry, intended for a small
  number of patients suffering from rare
  conditions.
• Increasing sales of prescription drugs,
  substantial benefits for new entrants in rare
  disease drug market, increased spending on
  medicines, rising healthcare expenditure and
  improving economic conditions of nations are some
  of the significant factors driving growth of the
  Orphan drugs market. However, the growth of the
  market is hindered by certain challenges
  including tougher regulatory approvals,
  limitation on charging higher prices and no
  approved drugs for several rare diseases
  including Polychethemia Vera (PV).
• The global orphan drugs market is expected to see
  numerous developments including approval of
  several Ultra-Rare drugs, increasing scope of
  Gene therapy, development of drugs for rare blood
  disease, higher success prospects for Hematology
  compared to Solid Tumors, attractive pricing
  option for orphan drug competitors and striking
  opportunities in developing orphan drugs.
• The report, Global Orphan Drugs Market analyzes
  the current prevailing condition of the market
  along with its future scope of development. The
  global market along with specific market of the
  U.S., Canada, Europe and Japan, is being
  discussed in the report. The major trends, growth
  drivers as well as issues being faced by the
  industry are being presented in this report. The
  major players in the industry are being profiled,
  along with their key financials and strategies
  for growth.

3
The development of orphan drugs has become an
important and attractive research and development
strategy of many pharmaceutical companies, as it
most commonly generates greater profitability due
to the recent development drivers
Global Orphan Drugs Market (2010-2015E)

• The global market for orphan drugs was estimated
  to have reached US... billion in the year 2015,
  increasing from US.. billion in the previous
  fiscal year recording an annual growth of for
  the year.
• For the year 2014, share of the overall orphan
  drugs market was held by biological orphan drugs
  followed by non-biological orphan drugs that held
  rest of the .. share.
• The average cost per person for an orphan and
  non-orphan drug was nearly US... thousand and
  US... thousand respectively for the year 2014,
  increasing from US... thousand and US..
  thousand respectively in the previous fiscal
  year.
• The median cost of orphan drugs per patient
  reached US.. thousand in the year 2014,
  increasing from US.. thousand in the previous
  fiscal.

Global Orphan Drugs Market by Type (2014)
The U.S. Prescription Pain Market Share by
Product Value (2014)
4
The significant factors driving growth include
governmental financial incentives including tax
credits, shorter clinical trial times with
smaller trial sizes, higher rate of regulatory
success and longer exclusivity periods
Non-Hodgkins Lymphoma (NHL) Incidence by Country
(2014)

• The total incidence for NHL reached thousand in
  the major economies increasing from thousand
  recording an annual growth of .
• The total spending on branded orphan drugs in the
  U.S. was estimated to have reached US... billion
  in the year 2014, increasing from US... billion
  in the previous fiscal year.
• The prevalence of LEMS (Lambert-Eaton Myasthenic
  Syndrome) in the U.S. was estimated to have
  reached in the year 2015, with a further
  expectation of reaching by the end of year 2020.
• The market for Firdapse drug for the treatment of
  LEMS in the U.S. is expected to start with sales
  worth US.. million in 2016, and reach US..
  million by the end of 2022.

The U.S. Orphan Drugs Spending (2009-2014E)
Prevalence of LEMS in the U.S. (2015-2020E)
5
The orphan drug spending in the U.S. will rise
aided by increasing approvals for orphan drugs by
health ministry, improved medical insurance
coverage and reimbursements for the treatment of
rare diseases.
Canadian Orphan Drug Spending (2009-2014E)

• The spending on branded orphan drugs in Canada
  was estimated to reach US.. million in the year
  2014, increasing from US... million in the
  previous fiscal year.
• The orphan drug spending in Canada was
  anticipated to have reached US.. million in the
  year 2015, recording an annual growth of ..
  with a further expectation of reaching US..
  million by the end of year 2018.
• The orphan drug designations per year in Japan
  reached .., increasing from .. in the previous
  fiscal year.
• In Europe, Non-Hodgkins Lymphoma was expected to
  be the most common indication with .. orphan
  designations followed by Leukemia, acute myeloid
  (AML) with and Cystic Fibrosis (CF) with .. And
  .. designations.

Japanese Orphan Drug Designation per Year
(2009-2014)
Orphan Drug Designation in the EU by Indication
(2014)
6
Contact Us
View Report Details
These are abridged and sanitized sample pages
from the comprehensive report on the Global
Orphan Drugs Market . To know more about this
report or for any customized research
requirement, please contact the following
Koncept Analytics CS-36, Second Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T.
91-120-4130959 C 91-9811715635
vikas_at_konceptanalytics.com
Vikas Gupta BD Manager
www.konceptanalytics.com